Boiron, the French homeopathic drug group, has reported a rise of 39.1% in net first-half 1995 profits to 19.9 million French francs ($3.9 million), on sales up 3.6% to 563.5 million francs. Foreign subsidiaries, excluding the group's Italian affiliate, contributed to growth of 26% in consolidated profits. A recent slowdown in sales in France has led to the group maintaining its net profits forecast for 1995 of 165 million francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze